ResearchPod Summary
Developing a cure for HIV requires purging the latent reservoir, where the virus remains transcriptionally silent in resting CD4+ T cells. Researchers use various in vitro cell models to screen for latency-reversing agents (LRAs) that can force the virus out of hiding. However, these models often yield conflicting results, and it remains unclear which, if any, accurately predict how drugs will perform in actual patient cells. This study aimed to systematically compare the response properties of multiple established latency models against patient-derived cells using a standardized panel of stimuli.
The researchers selected a diverse panel of 13 stimuli known to reactivate HIV through distinct signaling pathways, including T-cell receptor engagement, protein kinase C (PKC) activation, histone deacetylase (HDAC) inhibition, and P-TEFb release. They tested these stimuli in parallel across five primary T-cell models, four J-Lat cell line clones, and a quantitative viral outgrowth assay (QVOA) using resting CD4+ T cells from aviremic, ART-treated patients. The study used hierarchical clustering and heatmap visualization to identify similarities and differences in how these models respond to different drug classes.
The lack of a single, representative model for HIV latency is a major bottleneck in drug discovery. This study highlights that relying on a single cell model for screening can lead to misleading results, as a drug's efficacy is highly dependent on the specific signaling pathways active in that model. The findings suggest that a more rational approach to drug development involves using a combination of complementary models to better predict clinical outcomes.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.